Bladder Cancer Trial, Recruiting (NCT04368702)

Bladder Cancer Trial, Recruiting NCT04368702 Sponsor: Brigham and Women's Hospital Condition: Bladder Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT04368702 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Bladder Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

The person has a cancer diagnosis that has been confirmed by laboratory testing of cells or tissue, and the cancer requires radiation treatment.
The person is 18 years of age or older.
The person is well enough to carry out daily activities with minimal limitations (based on a standard health performance scale used by doctors).
The person is able to understand the study and is willing to sign a written consent form.
The person meets any additional criteria set out for their specific type of cancer within the trial (confirm with trial site).

Who may not be able to join:

The person has had an allergic reaction to gadolinium-based contrast dye used in scans (note: if contrast dye will not be used in the scan, this criterion does not apply).
The person experiences severe claustrophobia or anxiety that would prevent them from having a scan.
The person is unable to undergo an MRI scan for any reason.
The person meets any additional exclusion criteria set out for their specific type of cancer within the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 19 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Raymond Mak, MD, Dana-Farber Cancer Institute

Phone: 6177328651

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT04368702

Sponsor: Brigham and Women's Hospital

Phase: Not Applicable

Status: Recruiting

Condition: Bladder Cancer

Trial contact: 6177328651

More information: https://clinicaltrials.gov/study/NCT04368702

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

The person has a cancer diagnosis that has been confirmed by laboratory testing of cells or tissue, and the cancer requires radiation treatment.
The person is 18 years of age or older.
The person is well enough to carry out daily activities with minimal limitations (based on a standard health performance scale used by doctors).
The person is able to understand the study and is willing to sign a written consent form.
The person meets any additional criteria set out for their specific type of cancer within the trial (confirm with trial site).

Who may not be able to join:

The person has had an allergic reaction to gadolinium-based contrast dye used in scans (note: if contrast dye will not be used in the scan, this criterion does not apply).
The person experiences severe claustrophobia or anxiety that would prevent them from having a scan.
The person is unable to undergo an MRI scan for any reason.
The person meets any additional exclusion criteria set out for their specific type of cancer within the trial (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 19 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Brigham and Women's Hospital

Registry

ClinicalTrials.gov

Start date

1 May 2021

Est. completion

18 June 2029

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Patients and delivering MR-image guided radiation-Phase I; Tumor Assessment with MR Guidance-Phase I; Patient reported outcomes (PROMs) -Phase II; 1-year tumor control-Phase II; Rate of Pathologic complete response-Gastric

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov